Development in 2015 as expected under difficult framework conditions, says Stada Arz
The executive board of German drugmaker Stada Arzneimittel (SAZ: Xetra) confirmed preliminary figures for financial year 2015 and announced details on the development of segments.
“In addition to the two market regions Central Europe and Germany, the market region Asia/Pacific & MENA also showed very positive development with a strong sales increase in the double-digit percentage area. We were also able to significantly improve both our Group tax rate and cash flow from operating activities in financial year 2015,” said Hartmut Retzlaff, Stada’s chairman of the executive board about financial year 2015.
Sales and earnings
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze